Don't Miss Our New Year's Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Amylyx Pharmaceuticals Inc ( (AMLX) ) has provided an update.
Amylyx Pharmaceuticals Inc. has entered into a collaboration with Gubra A/S to develop a novel long-acting GLP-1 receptor antagonist. This partnership involves Amylyx making upfront and research payments and Gubra potentially receiving over $50 million in milestones and royalties, with the collaboration expected to enhance Amylyx’s cash runway into 2026.
More about Amylyx Pharmaceuticals Inc
Amylyx Pharmaceuticals Inc. operates in the pharmaceutical industry, focusing on the development of innovative therapies to address neurological diseases.
YTD Price Performance: -73.71%
Average Trading Volume: 1,292,823
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $265.3M
See more insights into AMLX stock on TipRanks’ Stock Analysis page.
Trending Articles
- Netflix (NASDAQ:NFLX) Lands Huge Win With “Squid Game 2”
- Ford (NYSE:F) Lands New Patent for “Steer-by-Wire” System
- Intel (NASDAQ:INTC) Looking Into Battlemage Followup
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
